Quotient Clinical CEO Mark Egerton a Winner at UK EY Entrepreneur of the Year 2015 Awards
News Oct 08, 2015
Chosen by a panel of independent judges, the award acknowledges outstanding entrepreneurs who demonstrate excellence and extraordinary success in areas such as innovation, financial performance and personal commitment to their businesses and communities. Dr Egerton was one of 13 business leaders recognised for their achievements, and received his award at a special dinner held at The Brewery, London on the 5th of October.
Dr Egerton commented: “I am delighted to receive this honour in recognition of the high level of success that Quotient Clinical has achieved in recent years. The award acknowledges all of the hard work and dedication from everyone within the company. Thanks to an incredible team, we have repeatedly demonstrated that Translational Pharmaceutics® can deliver significant time and cost savings for our customers, helping them to increase their overall R&D productivity.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE